Background Psoriasis is a chronic, relapsing skin disease that may require multiple treatment courses. Alefacept targets the memory T cells implicated in psoriasis pathogenesis. This openlabel study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat courses of alefacept in men and women with chronic plaque psoriasis. This article reports the interim results of this ongoing study.
Introduction
Psoriasis is a chronic, relapsing skin disease that affects approximately 5.1 million individuals in Europe and more than 7 million in the USA. 1, 2 The National Psoriasis Foundation estimates that between $1.6 and $3.2 billion is spent each year in the USA on psoriasis treatments alone, and that the disease results in an annual loss of 56 million hours of work. 3 This significant economic burden is accompanied by reductions in the quality of life. 4 Individuals with psoriasis frequently experience physical symptoms (e.g. scaling, itching, skin redness), psychosocial problems (e.g. interacting with peers and family), and difficulty performing routine activities (e.g. exercising, sleeping, sexual activities). Nearly 80% of persons with severe psoriasis are negatively affected by their disease. 4 Psoriasis is now recognized as an immune-mediated disease in which memory effector (CD45RO + ) T cells play a critical role. 5, 6 Alefacept is a novel and selective biologic agent that targets this T-cell subset. It is a fully human fusion protein consisting of the first extracellular domain of lymphocyte function-associated antigen-3 (LFA-3) fused to the hinge, C H 2, and C H 3 sequences of IgG 1 . LFA-3 is a cell surface receptor found on immune accessory cells (e.g. natural killer cells, macrophages). The LFA-3 portion of alefacept binds to the CD2 receptor on T cells, thereby blocking their natural interaction with LFA-3 on antigen-presenting cells and thus inhibiting the antigen-dependent activation of T cells. 7 Alefacept also engages Fc γ RIII receptors on accessory cells. 8 Because CD2 expression is higher on memory than on naive (CD45RA + ) T cells, 9, 10 alefacept produces a selective apoptotic reduction in memory T cells. 11 As previously reported, a single course of intravenous alefacept was well tolerated and significantly improved psoriasis, with sustained clinical benefit after cessation of therapy. 11 Because of the long-lasting, relapsing nature of psoriasis, it is important to study the effects of repeat courses of alefacept. The primary objective of this study was to determine the safety and tolerability of repeat courses of intravenous alefacept in men and women with chronic plaque psoriasis who participated in previous phase II studies of alefacept. Efficacy and pharmacodynamic effects were secondary objectives. This article reports the interim results of this ongoing study.
Methods

Patients
Men and women with chronic plaque psoriasis who participated in previous phase II studies of alefacept were eligible for this retreatment study. Patients were eligible for the phase II studies if they had chronic plaque psoriasis that involved ≥ 10% of the body surface area which was diagnosed at least 12 months before study entry, were receiving systemic treatment or phototherapy or were candidates for such treatment, and had no serious hepatic or renal disease, history of cancer (basal cell carcinoma or less than three squamous cell carcinomas of the skin were permitted), or serious infection within the previous 3 months. Patients had to complete the 12-week treatment and observation phases of the phase II studies before being considered for the retreatment study.
Patients were not eligible for retreatment courses until their disease had returned to a level at which the investigator judged that systemic therapy or phototherapy was required. Alefacept treatment could only be started when CD4 + T-cell counts were at or above the lower limit of normal. The retreatment study was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent before enrolment. The local institutional review board at each participating site approved the protocol.
Study design
In the previous phase II studies, patients received one or two courses of alefacept or one course of placebo. A treatment course was defined as 12 weeks of once-weekly treatment followed by were not permitted to receive systemic psoriasis therapies, high-potency topical corticosteroids, or phototherapy at any time during the retreatment study.
Safety and tolerability assessments
All adverse events reported by the patient or observed by study personnel were recorded throughout the retreatment study. 
Efficacy assessments
The Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) were used to measure disease severity.
PASI scores, which range from 0 (no psoriasis) to 72 (the most severe disease possible), combine assessments of the extent of the body surface area affected and the degree of erythema, induration, and desquamation. 12 For PGA, a seven-point scale rating disease severity as "clear", "almost clear", "mild", "mild to moderate", "moderate", "moderate to severe", or "severe" was used. In retreatment course 1, PASI and PGA evaluations were performed before treatment, at 3, 5, 7, 9, 11, and 12 weeks during Clinical study Repeat courses of alefacept in psoriasis Lowe et al.
treatment, and at all follow-up visits. In subsequent retreatment courses, these evaluations were performed before treatment, at 7 weeks during treatment, and at 2 and 12 weeks during follow-up.
In each retreatment course, efficacy endpoints included the percentage of patients who achieved a ≥ 75% PASI reduction from baseline (defined as the baseline of retreatment course 1), a ≥ 50% PASI reduction from baseline, and PGA of "clear" or "almost clear" at 2 weeks after treatment cessation (primary endpoint).
Given that disease clearance with alefacept continues beyond the treatment period, 11 efficacy endpoints were also measured at any time after the first dose of alefacept (hereafter referred to as the overall response rates). 
Pharmacodynamic assessments
Results
Disposition and baseline characteristics
Patients who entered the retreatment study had received either alefacept ( n = 144) or placebo ( n = 30) in previous phase II studies. Of these patients, 174, 107, and 23 have thus far received at least one dose of alefacept during retreatment courses 1, 2, and 3, respectively. All patients were included in the safety analyses. The majority of patients in each course received all 12 doses of study drug (67% and 62% for retreatment courses 1 and 2, respectively); no patient has completed retreatment course 3 to date. Only two patients permanently discontinued because of low CD4 + T-cell counts (see "Safety and tolerability" section). Only patients who completed the 12-week follow-up phase of a course or withdrew from the study were included in the efficacy and pharmacodynamic analyses; at this time, 170 patients are evaluable in retreatment course 1, and 50 patients are evaluable in retreatment courses 1 and 2.
The mean age of the patients enrolled in this study was 45 years; 66% were male, and 84% were white. Patients had a mean weight of 95 kg and a mean height of 173 cm. At baseline, the median body surface area involvement of psoriasis ranged from 19% to 21% in the three retreatment courses, and the median PASI score ranged from 9.9 to 13.3. The baseline PGA was "moderate" or "moderate to severe" in 78%, 61%, and 57% of patients during retreatment courses 1, 2, and 3, respectively.
Safety and tolerability
Repeat courses of alefacept were similarly well tolerated. The most common adverse events were pharyngitis (13%) and rhinitis (13%) in retreatment course 1, and infection (7%) and pharyngitis (7%) in retreatment course 2 ( Table 1 ). The common cold was the most frequent event coded to "infection". There were no complicated or opportunistic infections. Rebound of disease or flare did not occur after completion of either retreatment course 1 or 2. No serious, drug-related adverse events were reported throughout the study.
Discontinuation rates because of adverse events were low (< 2%) in retreatment courses 1 and 2. Adverse events resulted in the discontinuation of three patients from retreatment course 1 (two for low CD4 + T-cell counts, one for pneumonia) and two patients from retreatment course 2 (one for herpes zoster, one for pulmonary fibrosis). The herpes zoster and pneumonia resolved with conventional treatment. The pulmonary fibrosis persisted. Because of low CD4 + T-cell counts, one patient was withdrawn after receiving two doses of alefacept (7.5 mg) and one dose of alefacept (3.75 Total number of patients completing retreatment courses 1, 2, and 3 are 174, 107, and 23, respectively. + T-cell counts, there were no accompanying adverse events of note.
Five patients had malignancies diagnosed during the study. One 65-year-old woman with a family history of colon cancer and a recent medical history of guaiac-positive stools was diagnosed with adenocarcinoma of the colon. A 66-year-old man with a history of heavy smoking was diagnosed with adenocarcinoma of the lung. Three patients with long-standing psoriasis (19-34 years) and previous exposure to psoralen plus ultraviolet A (PUVA) and methotrexate were diagnosed with squamous cell carcinoma of the skin. All five patients received appropriate surgery and treatment.
There were no clinically important trends in medical history or physical examination findings, vital signs, or standard laboratory test results. Of the 174 patients dosed in retreatment course 1, three (1.7%) tested positive for anti-alefacept antibodies after treatment initiation, one of whom tested positive before dosing. Two patients tested positive before dosing in retreatment course 1, but did not have a positive result after the start of therapy. Of the 107 patients dosed in retreatment course 2, one (< 1%) tested positive after beginning therapy. In all cases, titers were low and there was no association with safety issues.
Efficacy
In the previous phase II studies, alefacept significantly improved psoriasis symptoms. Alefacept had a consistent efficacy profile during repeat courses. Maximum mean reductions from baseline PASI were 51% at 6 weeks after the last dose of retreatment course 1, and 47% at 2 weeks after the last dose of retreatment course 2 (Fig. 1) . Retreatment course 2 baseline was lower relative to the baseline of retreatment course 1 (by approximately 30%), suggesting that patients who entered the second retreatment course of therapy had retained some clinical improvement from the first retreatment course. In retreatment course 1, overall response rates for patients achieving a PGA of "clear" or "almost clear", a ≥ 75% PASI reduction, and a ≥ 50% PASI reduction were 29%, 39%, and 66%, respectively (Fig. 2a) . Of the 50 patients who received two consecutive retreatment courses of alefacept, the percentage of patients who responded during the second course was consistent with or better than that Physician Global Assessment (PGA) of "clear" or "almost clear" and reductions in the Psoriasis Area and Severity Index (PASI) of ≥ 50% and ≥ 75% in patients retreated with intravenous alefacept during retreatment course 1 (a) and in patients who received two retreatment courses (b). The bars indicate the percentage of patients who achieved various degrees of improvement. In (b), only the 50 patients who completed both retreatment courses are included. The primary study endpoint was 2 weeks after the last dose and the overall response rate was defined as the response any time after the first dose of study drug Clinical study Repeat courses of alefacept in psoriasis Lowe et al.
observed during the first course (Fig. 2b) . In both retreatment courses, patients continued to improve after the dosing interval. A higher percentage of patients had a ≥ 75% decrease in PASI at 12 weeks post-dosing than at any time during the dosing interval or 2 weeks after the last dose (primary endpoint) (Fig. 3) .
Pharmacodynamics
Alefacept reduced total lymphocyte and lymphocyte subset counts to a similar extent over both retreatment courses. + natural killer cells or CD19 + B cells throughout the study. Ninety-eight per cent of patients had total lymphocyte counts at or above the lower limit of normal at 12 weeks after the last dose, regardless of retreatment course; 94% and 92% of patients had CD4 + T-cell counts at or above the lower limit of normal at 12 weeks after the last dose of retreatment courses 1 and 2, respectively.
Discussion
Psoriasis is a chronic disease with, as yet, no cure. Treatments are available to reduce or suppress the symptoms, but do not provide long-lasting disease remission. Currently available agents for psoriasis are generally efficacious, but safety, tolerability, and the need for regular laboratory or other evaluations are often a concern. Cyclosporine is nephrotoxic, particularly with long-term use, 13 while methotrexate is associated with bone marrow toxicity during short-term use and hepatotoxicity during extended use.
14 Both of these agents can also interact with a variety of drugs, thereby increasing the potential for toxicity. 15 Retinoids are teratogenic, invariably produce mucocutaneous side-effects, and are less efficacious than cyclosporine or methotrexate. 16 PUVA use is associated with a dose-related increase in the risk of squamous cell carcinoma 17 and possibly melanoma. 18 These data underscore the need for safer and better tolerated, longer term psoriasis therapies, thus benefiting a patient's quality of life.
Alefacept was well tolerated when used in repeat 12-week courses for the treatment of chronic plaque psoriasis. The most common adverse events in this retreatment study were pharyngitis, rhinitis, and infection, which was most commonly associated with a cold. No opportunistic infections, rebound of disease, or flares were reported. The patient in whom lung fibrosis was diagnosed had a 24-year history of coal dust exposure and a history of pneumonia, both of which were thought to have contributed to the fibrosis. The patient also had a significant smoking history. Five cases of malignancy (two systemic, three skin) were reported in the study; in each case, there were additional risk factors that probably contributed to the occurrence. In addition, the incidence of these cancers is similar to that expected in untreated individuals of the same age. A total of 22 patients of at least 60 years of age were enrolled in this study, and the incidences of colon and lung cancer in this age group are approximately 1 in 25 and 1 in 16, respectively. 19 Consistent with its fully human protein composition, the immunogenicity of alefacept was very low. Although this was an open-label study, the efficacy results of the first retreatment course, with overall response rates of 39% for patients achieving a ≥ 75% reduction in PASI from baseline and 66% with a ≥ 50% reduction, are consistent with those of a previous randomized, placebo-controlled, double-blind study. 11 The overall response rates as defined in this study are likely to be more important to patients and physicians in clinical practice compared with response rates measured at a single time point. Alefacept provided consistent clinical benefit following one or more retreatment courses. Patients had either an equivalent clinical response or further improvement after a second retreatment course. Efficacy increased over time in both retreatment courses. There was no evidence of tachyphylaxis.
Patients entering the second retreatment course had a lower disease burden relative to those entering the first retreatment course, as suggested by the 30% lower mean baseline PASI score, indicating a sustained treatment benefit. The results support those of a previous study suggesting that alefacept is a remittive rather than suppressive therapy. 11 Remittive therapies have the advantage of increasing the time a patient is off medication and allowing for more disease-free living. PUVA and Goeckerman therapy are the only remittive therapies currently available; 20 -22 however, as mentioned previously, PUVA is associated with safety concerns, especially with longterm use; in addition, Goeckerman therapy is extremely time intensive for both the patient and physician and may require three or more weeks of daily, day-long sessions to induce remission. 22 As seen in other clinical studies, 11 alefacept selectively reduced memory T cells, with relative sparing of naive T cells. The mechanistic basis for this specificity involves at least two factors: the level of CD2 expression and the rate of replenishment of the different subpopulations. Memory T cells have higher CD2 expression relative to naive T cells. 9, 10 Both memory and naive T cells can regenerate, but the absolute rate of replenishment (> 10 8
−10
9 cells/day) is greater for naive T cells because of daily production by the thymus. 23 Over the multiple retreatment courses, a cumulative effect on lymphocytes or lymphocyte subsets was not observed. Nadirs and rates of recovery were similar with repeat dosing. A correlation between the extent of reduction in memory T cells and clinical response has previously been demonstrated, 11 supporting the belief that this T-cell population contains the clonal precursors that drive psoriasis disease activity. 6, 24 Maintaining excellent safety, tolerability, and efficacy over multiple courses of treatment is important because of the chronic and relapsing nature of psoriasis. Intravenous alefacept was well tolerated and had a consistent safety and tolerability profile during repeat courses. The clinical response to alefacept was consistent amongst patients who received two retreatment courses, with a trend for additional benefit in retreatment course 2. Repeat courses of alefacept selectively reduced memory T cells without cumulative effects.
